Construction of an integrated prognostic classifier model for predicting the efficacy of immune checkpoint inhibitor therapy in non-small cell lung cancer.

Cancer Commun (Lond) · 2020 · PMC7427306 · PMID 32639662

Europe PMC DOI

hedged sentence

0.1960

closest p · 3.9× alpha

0.1960

boldest claim

The sentences

did not reach statistical significanceP = 0.196not close (p > 0.1)

The response rate was 14.3% for ARID1B mutant patients versus 0% for ARID1B wild‐type patients, but probably because of the small sample size (34 in total), results did not reach statistical significance ( P = 0.196).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.